Abstract: The present disclosure relates to a control circuit of a heating apparatus, including a heating control unit, a heating unit, a main control integrated circuit (IC), and a turn-on/off switching unit. The heating control unit is configured to connect or disconnect a path between an external mains supply and the turn-on/off switching unit. The heating unit is connected to the main control IC or the heating control unit via the turn-on/off switching unit. The main control IC is configured to detect an internal resistance of the heating unit, and to control the heating control unit to be turned off when the detected internal resistance exceeds a preset range, thereby improving the safety.

Abstract: The present invention relates to a compound of formula (I) capable of inhibiting plasmin activity and having blood coagulation and hemostasis activity, and a pharmaceutically acceptable salt, hydrate, isomer, prodrug and mixture thereof, wherein R1 to R3 are as defined in the description.

Abstract: Discovery of a new Bax isoform, Bax?2, in cancer cell lines and primary tumors is described. The Bax?2 isoform resulted from combination of Bax microsatellite mutation and alternative splicing Bax exon 2. It is also discovered that Bax?2 renders cancer cells sensitive to certain chemotherapeutic drugs that target caspase 8. Also provided are methods for treating colorectal cancer by administering to a colorectal cancer patient a chemotherapeutic agent that is capable of activating caspase 8, wherein the patient contains a cancer cell that expresses a Bax?2 protein (SEQ ID NO. 2).

Abstract: Discovery of a new Bax isoform, Bax?2, in cancer cell lines and primary tumors is described. The Bax?2 isoform resulted from combination of Bax microsatellite mutation and alternative splicing Bax exon 2. It is also discovered that Bax?2 renders cancer cells sensitive to certain chemotherapeutic drugs that target caspase 8. Also provided are methods for treating colorectal cancer by administering to a colorectal cancer patient a chemotherapeutic agent that is capable of activating caspase 8, wherein the patient contains a cancer cell that expresses a Bax?2 protein (SEQ ID NO. 2).

Abstract: Discovery of a new Bax isoform, Bax?2, in cancer cell lines and primary tumors is described. The Bax?2 isoform resulted from combination of Bax microsatellite mutation and alternative splicing Bax exon 2. It is also discovered that Bax?2 renders cancer cells sensitive to certain chemotherapeutic drugs that target caspase 8. Also provided are methods for treating colorectal cancer by administering to a colorectal cancer patient a chemotherapeutic agent that is capable of activating caspase 8, wherein the patient contains a cancer cell that expresses a Bax?2 protein (SEQ ID NO. 2).

Abstract: The present invention provides a pharmaceutical composition, comprising a recombinant adenoviral vector encoding an pro-apoptotic Bax gene and a pharmaceutically acceptable carrier. Further is provided a method of treating an individual having a pathophysiological state, comprising the step of administering to said individual a pharmacologically effective dose of this composition.